Marker Therapeutics, Inc. — Director's Dealing 2018

Oct 17, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TAPIMMUNE INC. (TPIV)
CIK: 0001094038
Period of Report: 2018-10-16

Reporting Person: Reddish Mark (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-10-16	Common Stock	A	4106	—	Acquired	36110	Direct

Footnotes

F1: Represents the pro-rated portion of the annual board retainer for each non-employee director payable in immediately vested, common stock under the Company's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $7.74 per share, on the day immediately preceding the date of the Company's 2018 annual meeting.